Skip to main content
Erschienen in: World Journal of Urology 1/2018

23.10.2017 | Original Article

Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis

verfasst von: Marco Bandini, Raisa S. Pompe, Michele Marchioni, Zhe Tian, Giorgio Gandaglia, Nicola Fossati, Derya Tilki, Markus Graefen, Francesco Montorsi, Shahrokh F. Shariat, Alberto Briganti, Fred Saad, Pierre I. Karakiewicz

Erschienen in: World Journal of Urology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Contemporary data regarding the effect of local treatment (LT) vs. non-local treatment (NLT) on cancer-specific mortality (CSM) in elderly men with localized prostate cancer (PCa) are lacking. Hence, we evaluated CSM rates in a large population-based cohort of men with cT1-T2 PCa according to treatment type.

Methods

Within the SEER database (2004–2014), we identified 44,381 men ≥ 75 years with cT1-T2 PCa. Radical prostatectomy and radiotherapy patients were matched and the resulting cohort (LT) was subsequently matched with NLT patients. Cumulative incidence and competing risks regression (CRR) tested CSM according to treatment type. Analyses were repeated after Gleason grade group (GGG) stratification: I (3 + 3), II (3 + 4), III (4 + 3), IV (8), and V (9-10).

Results

Overall, 4715 (50.0%) and 4715 (50.0%) men, respectively, underwent NLT and LT. Five and 7-year CSM rates for, respectively, NLT vs. LT patients were 3.0 and 5.4% vs. 1.5 and 2.1% for GGG II, 4.5 and 7.2% vs. 2.5 and 2.8% for GGG III, 7.1 and 10.0% vs. 3.5 and 5.1% for GGG IV, and 20.0 and 26.5% vs. 5.4 and 9.3% for GGG V patients. Separate multivariable CRR also showed higher CSM rates in NLT patients with GGG II [hazard ratio (HR) 3.3], GGG III (HR 2.6), GGG IV (HR 2.4) and GGG V (HR 2.6), but not in GGG I patients (p = 0.5).

Conclusions

Despite advanced age, LT provides clinically meaningful and statistically significant benefit relative to NLT. Such benefit was exclusively applied to GGG II to V but not to GGG I patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
5.
Zurück zum Zitat Carroll PR, Parsons JK, Andriole G et al (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Cancer Netw 14:509–519CrossRef Carroll PR, Parsons JK, Andriole G et al (2016) NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Cancer Netw 14:509–519CrossRef
6.
Zurück zum Zitat Scosyrev E, Messing EM, Mohile S et al (2012) Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118:3062–3070. doi:10.1002/cncr.26392 CrossRefPubMed Scosyrev E, Messing EM, Mohile S et al (2012) Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118:3062–3070. doi:10.​1002/​cncr.​26392 CrossRefPubMed
8.
Zurück zum Zitat National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group, Adamo MP, Boten JA et al (2017) Validation of prostate-specific antigen laboratory values recorded in surveillance, epidemiology, and end results registries. Cancer 123:697–703. doi:10.1002/cncr.30401 CrossRef National Cancer Institute Surveillance, Epidemiology, and End Results Prostate-Specific Antigen Working Group, Adamo MP, Boten JA et al (2017) Validation of prostate-specific antigen laboratory values recorded in surveillance, epidemiology, and end results registries. Cancer 123:697–703. doi:10.​1002/​cncr.​30401 CrossRef
9.
10.
Zurück zum Zitat Leyh-Bannurah S-R, Budäus L, Pompe R et al (2017) North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate 77:542–548. doi:10.1002/pros.23292 CrossRefPubMed Leyh-Bannurah S-R, Budäus L, Pompe R et al (2017) North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. Prostate 77:542–548. doi:10.​1002/​pros.​23292 CrossRefPubMed
11.
Zurück zum Zitat Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 103:217–222. doi:10.1016/j.radonc.2012.01.007 CrossRef Hoskin PJ, Rojas AM, Bownes PJ et al (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 103:217–222. doi:10.​1016/​j.​radonc.​2012.​01.​007 CrossRef
13.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974CrossRefPubMed
20.
Zurück zum Zitat Wong L-M, Tang V, Peters J et al (2016) Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort. BJU Int 117(Suppl 4):82–87. doi:10.1111/bju.13460 CrossRefPubMed Wong L-M, Tang V, Peters J et al (2016) Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort. BJU Int 117(Suppl 4):82–87. doi:10.​1111/​bju.​13460 CrossRefPubMed
25.
Zurück zum Zitat Liu L, Coker AL, Du XL et al (2008) Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. J Surg Oncol 97:583–591. doi:10.1002/jso.21028 CrossRefPubMed Liu L, Coker AL, Du XL et al (2008) Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. J Surg Oncol 97:583–591. doi:10.​1002/​jso.​21028 CrossRefPubMed
27.
Zurück zum Zitat Herlemann A, Buchner A, Kretschmer A et al (2017) Postoperative upgrading of prostate cancer in men ≥ 75 years: a propensity score-matched analysis. World J Urol. doi:10.1007/s00345-017-2045-1 Herlemann A, Buchner A, Kretschmer A et al (2017) Postoperative upgrading of prostate cancer in men ≥ 75 years: a propensity score-matched analysis. World J Urol. doi:10.​1007/​s00345-017-2045-1
28.
Zurück zum Zitat Busch J, Magheli A, Leva N et al (2014) Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int 114:517–521. doi:10.1111/bju.12466 CrossRefPubMed Busch J, Magheli A, Leva N et al (2014) Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int 114:517–521. doi:10.​1111/​bju.​12466 CrossRefPubMed
Metadaten
Titel
Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis
verfasst von
Marco Bandini
Raisa S. Pompe
Michele Marchioni
Zhe Tian
Giorgio Gandaglia
Nicola Fossati
Derya Tilki
Markus Graefen
Francesco Montorsi
Shahrokh F. Shariat
Alberto Briganti
Fred Saad
Pierre I. Karakiewicz
Publikationsdatum
23.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-017-2102-9

Weitere Artikel der Ausgabe 1/2018

World Journal of Urology 1/2018 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.